Tag Archives: LYNPARZA: ASTRAZENECA GETS EU BACKING FOR BREAST CANCER THERAPIES

AstraZeneca said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio. Lynparza, a cancer drug developed jointly with US-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically …

Read More »